Supervisory Board
Chairman of the Board
Chairman of the Board
Udo J. Vetter has been a member of ITM's Supervisory Board since 2006 and its Chairman since 2007. As one of the founding members of the company, he has been instrumental in the establishment and development of ITM as a vertically integrated biopharmaceutical company through his broad pharmaceutical expertise and strategic advice.
After graduating from the University of Washington in Seattle with a degree in clinical pharmacy, Mr. Vetter spent five years as a pharmacist at Schering-Plough Corp. (now Merck & Co. Inc.), where he was responsible for establishing manufacturing facilities in Puerto Rico. He then served as Vice President of Licensing and Manufacturing for Martec, Inc. and President of Vetter Pharm-Turm Inc.
Since 1987, he has held various senior management positions at Vetter and has been Chairman of the Board since 2008. In addition, he founded the investment company UV-Cap in 2004. Today, Mr. Vetter is Chairman of the Supervisory Board of Navigo Proteins GmbH, OncoBeta International GmbH and a member of the professional associations ISPE (International Society of Pharmaceutical Engineering) and GPMLF (International Leadership Forum). He is also a member of the Supervisory Board of Gland Pharma/India and of the EBS Business School in Oestrich-Winkel, Germany.
In 2012, he became Vice President of Die Familienunternehmer in Germany and in May 2019, he was appointed President of European Family Businesses (EFB) in Brussels.
Vice Chairman of the Board
Vice Chairman of the Board
Steffen Schuster served as Chief Executive Officer of ITM from December 2011 to August 2024. During his tenure, he expanded the development and production of medical radioisotopes, transforming ITM from a pure radioisotope manufacturer into a global biotechnology and radiopharmaceutical leader. He also established key strategic partnerships, secured significant financing, and oversaw the opening of new sites in Germany and the United States.
Prior to his work at ITM, Mr. Schuster was a General Partner at TVM Capital. Before that, he served as the Chief Financial Officer of the publicly listed cycos AG. Earlier in his career, Mr. Schuster worked for the Siemens Network Division, where he held a variety of leading roles including international M&A as well as co-founder of the Mustang Ventures fund with headquarters in Silicon Valley where he acted as Managing Director and Investment Partner.
Mr. Schuster holds a Master’s Degree in Economics (Dipl.-Kfm.) from the University of Saarbrücken, Germany.
Oliver Buck is our founder and has served as a member of our Supervisory Board and as a senior advisor to us since September 2012. From 2005 to 2011, Mr. Buck served as our founding CEO. He is also the founder and Managing Director of the Buck Family office and consulting firm evo-partners GmbH since 2001. Mr. Buck is a serial entrepreneur and co-founder of various companies, including OncoBeta International GmbH, Munich Precision Oncology GmbH and Gaiaso Theranostics pty ltd. He currently serves on the board of directors and advisory boards of various private companies, including Optigo Biotherapeutics Inc., Navigo Proteins GmbH and OncoBeta International GmbH and Gaiaso Theranostics. He previously also served on the board of directors of Telix Pharmaceuticals Ltd. from its foundation to May 2022. He is also a co-founder of Global Bridges e.V. and a co-founder and a member of the board of trustees of the International Centers for Precision Oncology Foundation (the “ICPO Foundation”). Mr. Buck holds an advanced degree (Dipl.-Phys.) in Theoretical Physics from the Technical University of Munich and is an Alumnus of the German Federal Academy for Security Policies Core Seminar.
Michael Lee-Chin has served as a member of our Supervisory Board since May 2019. He is the founder and chairman of Portland Holdings Limited, a privately held investment company headquartered in Burlington, Ontario, Canada. Mr. Lee-Chin is also a director of NCB Financial Group Limited and Guardian Holdings Limited. Mr. Lee-Chin holds a Bachelor of Engineering degree from McMaster University. We believe Mr. Lee-Chin’s experience in executive leadership qualifies him to serve on our Supervisory Board.
“Ethan” Jung Ryun Park
“Ethan” Jung Ryun Park has served as a member of our Supervisory Board since February 2023. Mr. Park is a Managing Director at Temasek, a global investment firm headquartered in Singapore. He is based in Singapore and leads the firm’s healthcare & life sciences investment activities in Europe, Middle East, Africa and Southeast Asia. Previously, he worked at SK Corporation in Seoul, Korea. Mr. Park currently serves on the boards of several healthcare companies. Mr. Park holds a B.A. from Tufts University, where he was a member of Phi Beta Kappa and graduated magna cum laude, and an M.S. from the London School of Economics and Political Science. He also received an international diploma from the Institut d’Etudes Politiques de Paris (Sciences Po).
Manuel Salvisberg has served as a member of our Supervisory Board since November 2016. He has served as the managing director of the family office of Dr. Uli Sigg in Switzerland and Hong Kong since 2006. From 2005 to 2006, Mr. Salvisberg worked as an associate at Boston Consulting Group in strategy consulting. Mr. Salvisberg is a Chartered Financial Analyst and Chartered Alternative Investment Analyst. He also serves as a chairman and board member of various healthcare, software and asset management companies internationally, including on the advisory board of OncoBeta GmbH. He holds a Master’s degree in Finance, Reporting and Controlling from the University of St. Gallen.
Tadd Wessel is the founder and Managing Partner of Petrichor, a private equity firm focused on the healthcare sector. He is also a founder and Managing Partner of Scion Life Sciences, an affiliate of Petrichor. Tadd has more than 25 years of experience, primarily focused on investing and building companies in the life sciences sectors. Previously, he was a Partner at OrbiMed Advisors where he led the build-out of the structured investment business. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group. Tadd began his career in the life sciences investment banking groups at Citigroup and Robertson Stephens. Tadd has served on more than 30 boards, most recently including Aurion Biotech, Cryoport (NASDAQ: CYRX), and ITM. He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma. He also serves on the board of the ICPO Foundation, whose mission is to scale access of molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients globally.